Triple-negative breast cancer (TNBC), a fast-growing and highly aggressive form of the disease, affects approximately 15% of breast cancer patients. The subtype disproportionately impacts women of color, patients under 40, and individuals carrying the BRCA1 gene mutation. TNBC is notoriously difficult to treat because its cells lack estrogen, progesterone, and HER2 receptors.
A recent preclinical study published in NAR Cancer offers hope for a breakthrough treatment. Researchers at Bound Therapeutics and the University of Pennsylvania have developed a serum-stable drug using an oligo-peptide conjugate approach that targets and silences overexpressed microRNAs (miRNAs) in TNBC. The team, led by Yuanyuan Jin, believes the therapy could succeed where conventional drugs for HER2-positive and other breast cancer types have fallen short.
Targeting the “Master Regulators” of Cancer
MiRNAs are short, noncoding RNA sequences that regulate gene expression by inducing mRNA degradation. Nobel Prize winners Victor Ambros and Gary Ruvkun were recognized in 2024 for their discovery of these regulatory RNAs and their role in human health.
“MicroRNAs regulate hundreds of mRNAs simultaneously,” said Eric Wickstrom, corresponding author of the study. “miR-21, in particular, sits at the top of the cell growth pyramid in cancer cells.”
The team focused on inhibiting miR-21 using an antisense oligonucleotide (ASO). This microRNA is known to promote tumor growth, metastasis, immune evasion, and treatment resistance. Blocking miR-21, Jin explained, “allows a single therapy to interfere with multiple survival pathways simultaneously.”
Enhancing Precision with a “Trojan Horse” Delivery System
To further improve the drug’s efficacy, the researchers conjugated the miR-21 inhibitor with an insulin-like growth factor 1 (IGF1) peptide analog. IGF1 receptor overexpression is associated with TNBC and poor prognosis. The conjugate enables the drug to home in on TNBC cells, bind to IGF1R, and enter cells efficiently. Jin likened the mechanism to a “Trojan horse,” delivering the RNA payload directly inside cancer cells for maximum effect.
Existing FDA-approved therapies, including PARP inhibitors and immune checkpoint blockers, have limited impact, especially for patients without BRCA mutations. “For most people with TNBC, these drugs don’t work,” Jin said. “Cancer can adapt by switching pathways, which allows it to keep growing.”
Overcoming Previous miRNA Therapy Challenges
MiRNA-targeting drugs have faced hurdles such as toxicity, instability, and poor delivery. The team addressed these issues using a bridged nucleic acid (BNA) structure, which stabilizes the RNA and enhances binding to its target.
“Our BNA chemistry locks the RNA into the correct shape, allowing it to grip miR-21 tightly and resist breakdown,” said Jin. “This eliminates the need for lipid or nanoparticle carriers.”
In preclinical tests, the miR-21 inhibitor oligo (BND5412) reduced cell viability and proliferation across seven TNBC cell lines representing roughly 80% of patient cases. Cytotoxicity and apoptosis increased, while tumor growth in mice decreased significantly without observed side effects.
The miR-21-BNA-IGF peptide conjugate (BND6482) delivered even more dramatic results. After a two-week in vivo course, tumor progression halted and mean tumor mass dropped by 74%. Imaging and tissue analyses confirmed that the drug accumulated predominantly in tumors, sparing healthy organs.
Subtype-Specific Effects and Immune Checkpoint Insights
TNBC is not a single disease but comprises at least six molecular subtypes, each driven by different survival pathways. The study also evaluated the effect of miR-21 inhibition on key immune checkpoint proteins—PD-L1, PD-L2, CD47, and JAK2.
Mesenchymal stem-like TNBC subtypes showed the most significant reductions across all checkpoints, while other subtypes exhibited variable responses. These findings suggest that treatment success may depend on both tumor subtype and immune signaling patterns, potentially guiding future patient stratification.
Next Steps
While preclinical results are promising, human trials will be essential to confirm the drug’s safety and efficacy. TNBC’s ability to develop treatment resistance through complex signaling pathways, including immune checkpoints, poses a challenge. Researchers are hopeful that miR-21 inhibition could provide a multi-targeted approach to outsmart these survival mechanisms and offer a much-needed option for patients with aggressive breast cancer.
